Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (80688)	5/14/2000 9:43:00 PM
From: Knighty Tin	Read Replies (1) \| Respond to of 132070

Spek, They have just STARTED selling the biggest product in their history. Obviously, that was an enormous investment in cash, which is why they are tapping the market for funds, which is also hitting the stock. The total market for Cenestin is so huge and their generic is so much cheaper than the J&J product that they will make a ton of money as this roll-out picks up steam. In other words, we are here on or near launching date and it is way too early to call this rocket a flop. Small companies often have losses as they develop products that have to compete with giants. With the graying of America, there will be more women going through menopause and with the planned health scamsters trying to cut costs, a generic in this market could be golden.